Antibody Discovery Platform -- One of the outstanding features of Alpha Lifetech's biotechnology platform is its advanced antibody discovery capabilities. By leveraging matured technology, the platform enables rapid and efficient discovery of high-affinity antibodies against multiple targets.

Hybridoma Technology Platform -- The platform’s utilization of Hybridoma technology makes it a game-changer for the industry. By fusing B cells with myeloma cells, Alpha Lifetech's platform generates hybridomas capable of producing monoclonal antibodies with exceptional specificity and functionality. Traditional antibody production enables us gain titer guaranteed antiserum.

Single B Cell Platform -- This platform provides an unparalleled level of precision and customization. By isolating and analyzing individual B cells, researchers can discover rare and potent antibodies, allowing the development of next-generation biologics with enhanced therapeutic potential.

Membrane Protein Platform -- Alpha Lifetech's platform excels in the challenging field of membrane protein research. The platform's expertise enables the isolation and characterization of antibodies directed against membrane proteins, which are notoriously difficult antibodies to work with. We find new possibilities for drug discovery and the study of complex biological processes.